alpha-L-iduronidase
Orphan Drug Cold Chain RequiredFDA Approved, EMA Approved
Description
Aldurazyme is an enzyme replacement therapy for mucopolysaccharidosis I (MPS I). While primarily indicated for MPS I, it has been studied in related lysosomal storage disorders including fucosidosis due to similar pathophysiology. The recombinant enzyme helps break down glycosaminoglycans that accumulate in affected tissues.
Indications & Therapeutic Use
Mucopolysaccharidosis I, lysosomal storage disorders
Linked Diseases:
fucosidosis
D005645
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
alpha-L-iduronidase
| Generic Name | alpha-L-iduronidase |
| Brands | 1 brand available |
| Active Ingredient | laronidase |
| Drug Class | Mucopolysaccharidosis I |
| Manufacturer | BioMarin Pharmaceutical Inc. |
| Dosage Forms | IV infusion, 0.58 mg/mL |
| Medical Code | A16AB05 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00001203 |
| Countries | 8 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations9 Validated Nodes